XXXIX. Imunoanalytické dny, mezinárodní konference
Plzeň, PRIMAVERA Hotel & Congress centre****, 11.–13. března 2018
ImunoDny
English

Organizace

Společnosti podílející se na organizaci konference:

  • Česká společnost nukleární medicíny ČLS JEP
  • Česká společnost klinické biochemie ČLS JEP

Záštita

Záštitu nad konferencí převzali:

  • prof. MUDr. Tomáš Zima, DrSc., MBA
    Rektor Univerzity Karlovy
  • prof. MUDr. Štěpán Svačina, DrSc., MBA
    Předseda ČLS JEP, z.s.
  • MUDr. Václav Šimánek, Ph.D.
    Ředitel Fakultní nemocnice Plzeň

List of speakers (alphabetical order)

Vivian Barak, Professor, MD., PhD.

  • Prof. Barak received her Ph.D.in Immunology, Hebrew University-Medical School, Jerusalem, Israel

From 1985-now is a head of Immunology& Tumor Diagnosis Lab, Oncology Dept, Hadassah Medical Center. Between 1992-2000 worked as a Lecturer in Oncology, Hebrew University -Medical School, Jerusalem, Israel and from 2005-now she is an Associate Professor in Oncology, Hebrew University- Medical School, Jerusalem, Israel. Prof. Barak is a head of Israeli Cytokine Standardization Laboratory, and Israeli Tumor Markers Standardization Laboratory.

She is a member of editorial boards of international journals, International organizations and Scientific committees (ISOBM, EGTM, IIAR).

Prof. Barak published 230 papers in International Journals and 16 – in Israeli Journals.

Karl-Friedrich Becker, Professor, PhD.

  • Institute of Pathology, Technische Universität München, Trogerstrasse 18, München D-81675, Germany
  • email: kf.becker@tum.de
Karl-Friedrich Becker, Professor, PhD.

Karl-Friedrich Becker heads the Laboratory for Experimental Pathology at the Technical University of Munich. His lab uses unique methods for protein analysis of tissues, e.g. extraction of intact proteins from formalin-fixed and paraffin-embedded (FFPE) tissues and Reverse Phase Protein Arrays (RPPA), for which he was awarded with the Novartis Research Prize for Pathology.

Since 2012 Dr. Becker is member and project leader of the European Committee for Standardization (CEN) TC140 „In vitro diagnostic medical devices“, WG3 „Quality Management in the Medical Laboratory“ and since 2014 member and project leader of the International Organization for Standardization (ISO) TC212 “Clinical laboratory testing and in vitro diagnostic test systems”.

Since June 2016 Dr. Becker is Scientific Director of the Tissue Biobank of the Medical School of the Technical University of Munich. 125 publications listed in PubMed | 8861 citations | H-index: 46

Christoph Brochhausen, Professor, MD

  • Institute of Pathology, University Regensburg, Franz Josef Strauß Allee11, Regensburg, D-93053, Germany,
  • email: christoph.brochhausen@ukr.de
Christoph Brochhausen, Professor, MD

Christoph Brochhausen is Vice Director of the Institute of Pathology at the University Regensburg. Since 2018 he holds a professorship for pathology at the University Regensburg focusing on Digital Pathology, Tissue Banking and Tissue Engineering. His lab uses modern techniques in digitalization and engineering, e.g. Whole Slide Imaging, three dimensional image reconstruction, and in vitro modelling, for which he was awarded with the “Ars legendi Award” of the German Medical Faculty day (2015), the Histalim Award (2015) and as a landmark in the Land of Ideas (2012).

Since 2015 Professor Brochhausen is member of the German Committee of Standardization (“Biobanks and Biorepositories”).

Since 2018 Prof. Brochhausen is head of the Central Biobank of the University Regensburg.

130 per-reviewed articles | 1700 citations | H-index: 23

Eleftherios P. Diamandis, Professor, MD, PhD.

Eleftherios P. Diamandis, Professor, MD, PhD.

Dr. Diamandis currently serves as Division Head of Clinical Biochemistry at Mount Sinai Hospital and Biochemist-in-Chief at the University Health Network and is Professor & Head, Clinical Biochemistry, Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada. His research activities evolve around discovery and validation of cancer biomarkers, proteomics, mass spectrometry and translational research.

Dr. Diamandis received his B.Sc. in Chemistry, Ph.D. in Analytical Chemistry and M.D. from the University of Athens, Greece and a Diploma in Clinical Biochemistry from the University of Toronto, Canada. He is a Certified Clinical Chemist by the Canadian Academy of Clinical Biochemistry and the American Board of Clinical Chemistry.

Dr. Diamandis is a Member of 45 Journal Advisory Scientific and Editorial Boards. He has received numerous awards from both national and international organizations He has more than 51,000 lifetime citation and an H-index of 112.

Other major distinctions of Dr. Diamandis include his election as Corresponding Member of the Academy of Athens, Greece (2005), Member of the Royal Society of Canada (2008). Fellow of the American Association for the Advancement of Science (2011) and Fellow of the Canadian Academy of Health of the Sciences (2012). He has published 150 review papers, over 600 research papers and co-authored 4 books and 42 book chapters. He is the inventor of 28 issue and 26 pending patents and supervised 22 MSc. and 42 PhD. theses.

The research interests of Dr. Diamandis are as follows:

  1. Kallikrein Biology and Pathophysiology
  2. Proteomics
  3. Tumor Markers
  4. Mechanisms of Carcinogenesis and Metastatic Progression
  5. Translational Research
  6. Cancer Therapeutics
  7. Male Infertility
  8. Pathobiology and Biomarkers of Autoimmune Diseases
  9. Neurodegeneration

Professor M Joe Duffy

Professor M Joe Duffy

Professor Duffy who is based at St Vincent’s University Hospital, Dublin and University College, Dublin has extensive experience in oncological molecular therapeutics and biomarkers. He has published in excess of 250 papers on these topic, including articles in high impact journals such as Lancet, BMJ, J Natl Cancer Instit, Cancer Res, Clin Cancer Res, Ann Oncol and Clin Chem. His work has been cited < 16,000 times and his currently H-index is 71.

In 2012, Professor Duffy was the recipient of the 2012 Abbott Award of the International Society of Oncology and BioMarkers (ISOBM). This award is made annually to investigators, world-wide, who have made an outstanding contribution in the field of basic or clinical oncology research. Other awards received by Professor Duffy include the St Luke’s Medal Lecture, the Conway Review Medal Lecture and the Lifetime Achievement Award of the Royal Academy of Medicine in Ireland and the National Committee for Biochemistry Award Medal Lecture of the Royal Irish Academy.

Dr. habil. Magdalena Chechlińska

Dr. habil. Magdalena Chechlińska

Dr. Chechlinska is head of Department of Immunology at the Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology in Warsaw, Poland. She has published on cancer microenvironment, cytokines, microRNAs, with a special emphasis on biomarker search. In 2011, she was awarded the The Jedrzej Sniadecki Memorial Award of the Medical Department of the Polish Academy of Sciences for a series of papers on cancer biomarkers. She serves on the Editorial Board of BMC Cancer and Contemporary Oncology. She is a member of several Polish and International professional societies. She has been an invited speaker at a number of national and international conferences.

Associate professor RNDr. Judita Kinkorová, PhD.

Associate professor RNDr. Judita Kinkorová, PhD.

Dr. Judita Kinkorová is currently the manager of international research cooperation and affairs at University Hospital in Pilsen and Medical Faculty Charles University in Pilsen. She is a manager of the Biobank in Pilsen that is a member the biggest EU infrastructure, Biobanking and BioMolecular resources Research Infrastructure (BBMRI-ERIC) in Pilsen.

Her main areas of interest are personalized medicine, biobanking and biomarkers. Dr. Kinkorová studied Charles University in Prague, specialization biology-mathematics, holds a Ph.D from Czech University of Life Sciences in Prague. She worked at Charles University, faculty of natural sciences as a teacher and researcher, from 2007 as National Contact Point (NCP) for FP7, priority Health, and in 2014 Horizon 2020 societal challenge SC1 Health, demographic change and wellbeing at the Academy of Sciences of the Czech Republic, since 2015 is full employee in Pilsen (University Hospital and Medical Faculty). Dr. Kinkorová is involved in BRoTHER – Czech Bavarian cross border biobanking project.

Dr. Kinkorová is a member of EPMA (European Association for Preventive, Predictive and Personalized Medicine), ISOBM (International Society of Oncology and BioMarkers), EGTM (European Group of Tumor Markers), EBSS (European, Middle Eastern and African Society for Biopreservation and Biobanking), ISBER (International Society for Biological and Environmental Repositories).

Dr. Kinkorová is the author of 40 publications.

Prof. Dr. Rainer Klapdor

Prof. Dr. Rainer Klapdor

Prof. Klapdor is specialized in internal medicine with concentration to gastrointestinal physiology and oncology. The scientific work started in the middle of seventies with studies on bile acid metabolism, then changing to studies on enterohepatic circulation and gastrointestinal hormones and later to diagnosis and therapy of endocrine and exocrine tumors of the biliary-pancreatic axis. Since 1983 he is active in increasing work on tumor markers and organization of the Hamburg Symposia on Tumor markers (HSTM) regularly organised every year. Prof. Klapdor recieved several scientific awards and is a members in many professional societies.

Radek Kucera, Ph.D., Associate Professor

Radek Kucera, Ph.D., Associate Professor

He graduated from Charles University, Faculty of Pharmacy in Hradec Kralove in 1991 with the dissertation on the topic “Determination of digoxin using radioimunoanalytic methods.“ He took a Ph.D. degree in 2011 at Charles University, Faculty of Medicine in Pilsen with the doctoral thesis: “Insuline like and other growth factors and tumors.“ In January 2017 he finalized and defended his habilitation work on the topic “Insulin like growth factor I in theory and clinical practice“ and took the degree of associate professor.

In 1991 he started to work in the Department of Nuclear Medicine in the District Hospital of Klatovy. Since 2011 he has worked as an external lecturer of Faculty of Medicine in Pilsen. Since 2013 he has worked in the Department of Immunochemistry in University Hospital Pilsen. Nowadays, he works as vice head of the Department of Immunochemistry and teaches biochemistry at the Faculty of Medicine in Pilsen. He participates in research regarding hormones, growth factors and tumor markers. He is a member of the International Society of Oncology and Biomarkers (ISOBM). He is an author of more than 50 articles in medical journals with more than 130 citations in available literature, H-index 7.

Rafael Molina, MD, PhD.

Rafael Molina, MD, PhD.

Graduate in Medicina (University of Barcelona in 1979) and specialist on Clinical Pathology (Hospital Clinic 1983). In 1989 Dr Molina was Assistant Professor in the Department of Oncology, Health Science Center at San Antonio, Texas. Since 1996 is Assistant Professor of Biochemistry and Molecular Biology of the University of Barcelona and from 2002, president of the Biochemist Section of the Catalonian Academy of Medical Sciences. Dr. Molina is President and Board member of the ISOBM (International Society of Oncodevelopmental Biology and Medicine) and member of the editorial board of Tumor Biology, Journal of Biological Markers and Clinical Biochemistry. Likewise, Dr. Molina is the Chairman an active member of the European Group on Tumor markers (EGTM) and has been contribute to the publication of guidelines about the tumor marker use in Breast cancer and lung cancer in this group and in the NACB (National Academy of Clinical Biochemistry). He is member of the organizing committee of 18 International Congress or Symposiums and 20 courses about the clinical use of tumor markers. Dr. Molina is working in laboratory oncology from 1983 and is author of 175 original articles.

Andrea Nicolini*, MD, Aggregate Professor

  • at Department of Oncology, Pisa University, Pisa, Italy
  • *retired from Academy
Andrea Nicolini*, MD, Aggregate Professor

His research over the past 20 years was mainly devoted to the field of breast and colorectal cancer, particularly the use of serum tumor markers in the "early" detection and treatment of metastatic disease and the function of cell mediated immunity. The role of immunotherapy combined with conventional antiestrogen therapy to overcome the arising of resistance in endocrine dependent metastatic breast cancer was another main explored research field.

Dr.Nicolini has published about 250 original papers/review articles (including book chapters), most of them in peer reviewed Journals with I.F. He takes part of the Editorial Board of a few high rank scientific Journals and regularly serves as reviewer for them and many others.

Sarka Svobodova, MD, PhD.

Sarka Svobodova, MD, PhD.

She graduated at 1st Medical Faculty in Prague in 1993. During her studies she spent one year at UTHSCSA in San Antonio, Texas. She obtained the Internal Medicine– 1st degree specialization in 1998 and the licence for Internal Medicine in 2005. She worked as a resident at the 1st Internal Medicine Clinic, General University Hospital, Prague at the Department of the emergency medicine until 1999. Since 2002 she has been working as an Internal Medicine Specialist at the 3rd Internal Medicine Clinic, General University Hospital, Prague: particularly at Outpatient Clinic dedicated to metabolic syndrome and diabetes. She took a Ph.D. degree in 2009, with the doctoral thesis: “Regulation of parameters of biological activity of colorectal cancer.“ She is currently an assistant professor at the 1st Medical Faculty Charles University in Prague and at the Medical Faculty Charles University Pilsen, participating on issue of immunoanalytical methods. She is a member of European Association for Predictive, Preventive & Personalized Medicine – EPMA She has published more than 40 publications in medical journals. Her scientifically citation index:is 160 and H-index 9.

Ondrej Topolcan, MD, PhD.
Professor

Ondrej Topolcan, MD, PhD.

He graduated from the Medical Faculty, Charles University in Pilsen in 1967. Since 1993 he is a professor at the Medical Faculty Pilsen, Charles University. He worked as a head of 2nd Department of Internal Medicine in Pilsen (1996-2000). Since 2000 he has been working as a Head of the Central immunoanalytic and research laboratory Medical Faculty Pilsen. Since 2017 He is a Head of Department of imunochemistry Faculty hospital in Pilsen Member. He was a Member of Scientific committee Medical Faculty in Pilsen (1994 – 2012). Since 2009 he is a member of Scientific committee Endocrinology institut Prague. Since 2001 he is a Deputy director of Faculty hospital Pilsen for research and science. He was awarded in 2011 by Carl R. Jolliff Award for Lifetime Achievement in Clinical and Diagnostic Immunology the American Association for Clinical Chemistry (AACC). He is a member of European Group on Tumor Markers – EGTM, a member of International Society of Tumor Markers and Molecular Biology – ISOBM and a member of European Association for Predictive, Preventive & Personalized Medicine – EPMA. He has published more than 300 publications in medical journals and presented more than 410 lectures in medical conferences and congresses. His scientifically citation index is 2 456 and H-index 23.